Home
overview

For the latest COVID-19 Travel restrictions and recommendations please click here

SMi’s 4th Annual Conference
Injectable Drug Delivery 
11 - 12 May, 2022 | London, UK
-------------------------------------------------------------------------
As Part of Europe’s leading Injectable conference series, we will assess innovations in drug product formulation and biologics, new technologies in device design and the use of long-release injectable compounds.


There is a rising demand for vaccines, insulin,  and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027.


This year’s event will highlight innovations within the industry with regard to injectable device design and the formulation challenges of long-lasting, highly viscous and high volume drug delivery. There will be an additional focus on the impact that covid has had on advances within this industry over the past year. The conference will also highlight the significance of sustainability within the injectable drug delivery industry, whilst providing regulatory insight on the changes that have occurred.

  • Discover the new technologies and latest injectable devices being used within the industry 
  • Develop your understanding of high-volume and long-acting injectable compounds 
  • Explore the sustainable possibilities that can be adapted within the industry for a green future
  • Delve into the world of biologics and biosimilars and what these mean for the injectable drug market 
  • Network with key industry leaders and discover the leading companies within the injectables space
     

Advanz Pharma; Amgen; AstraZeneca; BD - Becton Dickinson; Bd Medical-Pharmaceutical Systems; BD Technologies and Innovation; Becton Dickinson; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & Co. KG; BSI Group; Chugai Pharmaceutical CO. LTD.; Congenius; Core Human Factors; F Hoffmann -La Roche Inc; GlaxoSmithKline; Glenmark Pharmaceuticals Inc.; GSK; Haselmeierá; Haughton Design Ltd; Ipsen Biopharm Limited; Janssen Pharmaceutica; Janssen Pharmaceutica NV; Legacy Allergan/AbbVie; LEO Pharma A/S; MedinCell; Merck; Merck Connected Health & Devices; MHRA; Micropore Technologies Ltd; Novartis / DD&C; Novartis International AG; Novo Nordisk Pharma; Owen Mumford; Pfizer UK Limited; Raumedic AG; Roche; SABIC; Sabic SHPP; Sandoz – A Novartis Company; Sanofi; Sanofi SWI; Team Consulting; Teva Pharamceuticals; UCB; Vetter Pharma-Fertigung GmbH & Co. KG; Zealand Pharma A/S;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Rene Holm

Rene Holm, Professor, University of Southern Denmark
View Bio

9:10 Impact of the EU MDR requirements on the risk management process for drug-device combination products

Fatima Bennai-Sanfourche

Fatima Bennai-Sanfourche, Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG

  • Regulatory landscape changes
  • EU MDR article 117 -Requirements
  • Requirements on device risk management process
  • Impact of the EU MDR on drug-device risk management process
  • Usability engineering/Human Factors (HF)
     
  • 9:50 Notified Body Expert Insight: The EU MDR one year on

    Julia Frese

    Julia Frese, Director, TUV SUD Japan Ltd.
    View Bio

  • Insights into notified body and industry experiences further to the EU MDR implementation
  • What are the main challenges that we have seen and how can industry work alongside Notified Bodies going forward?
  • Team-NB updates and insights on the injectable delivery regulatory environment
  • Looking to the future: Now that the EU MDR has been implemented where are the gaps in guidance and what is needed next?
     
  • 10:30 Morning Coffee

    11:00 Control of N-Nitrosamine Impurities in Human Drugs

    David Deutsch

    David Deutsch, Leading Senior Pharmaceutical Assessor, MHRA

  • What are nitrosamine impurities and why do we need daily limits?
  • Recalling of drugs by the manufacturer as recommended by regulatory bodies
  • Understanding the updated guidance on nitrosamines, what’s changed and what do industry need to consider?
  • Testing methods to detect nitrosamine impurities
  • Sources of the impurities and how they can be avoided
     
  • 11:40 Development of Medical Devices: A Toxicologists Perspective

    Clemens Gunther

    Clemens Gunther, Director, Senior Expert Nonclinical Safety, Bayer AG
    View Bio

  • Mastering the biocompatibility program
  • How to comply with requirements on Extractable & Leachable testing
  • Strategies to generate the Toxicological Risk Assessment
  • 12:20 Networking Lunch

    13:20 Injectable Long-Lasting Antipsychotic drugs for the treatment of Schizophrenia

    Rene Holm

    Rene Holm, Professor, University of Southern Denmark
    View Bio

  • How do long-lasting antipsychotics work within the body over time
  • Key considerations for long lasting injectable drug formulations
  • Altering the drug formulations for better treatment of schizophrenia
  • The benefit to patients of having long-last treatment for schizophrenia
  • 14:00 Overview of Development and Regulatory Landscape for On-Body Delivery Systems

    Prashant Bhatia

    Prashant Bhatia, Associate Director, AstraZeneca

  • Increase in demand for novel large-volume drug delivery devices
  • Development considerations for on-body injectors
  • Global overview on regulatory pathway for OBIs
  • Challenges for the industry with large-volume delivery devices
  • 14:40 Afternoon Tea

    15:10 Development of secondary packaging for combination products with an end-to-end thinking

  • What are the challenges in the development of secondary packaging for combination products?
  • Development process is an iterative, collaborative and user-driven approach with an end-to-end thinking
  • Success factor for development and technical transfer of secondary packaging
  • Learnings and best practice from secondary packaging development projects
  • Cristiana Heese

    Cristiana Heese, Packaging Engineer Combination Products, Boehringer Ingelheim Pharma Gmbh & Co. Kg

    Michael Becker

    Michael Becker, Packaging Engineer, Launch & Transfer Operations, Boehringer Ingelheim Pharma GmbH & Co. KG
    View Bio

    15:50 Chairman's Closing Remarks and Close of Day One

    Rene Holm

    Rene Holm, Professor, University of Southern Denmark
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Joel Richard

    Joel Richard, Chief Development Officer, MedinCell
    View Bio

    9:10 Long Acting Injectable Formulations of Fragile Drugs: Challenges and Opportunities for New Delivery Technologies

    Joel Richard

    Joel Richard, Chief Development Officer, MedinCell
    View Bio

  • The benefit of long-acting injectable formulations of fragile drugs for patients
  • Specific challenges for formulation of fragile drugs (peptides and proteins): short half-life, poor chemical stability, aggregation propensity, etc…
  • Successful technologies for long acting injectables and their limitations
  • Competitive advantages of new technologies based on injectable in situ forming implants
  • Case studies: recent progress in BEPO long acting injectable formulation development of peptides and proteins.
     
  • 9:50 Polymer vials - An alternative to glass for parenteral drugs?

  • Difference between materials - glass and polymer
  • Challenges for drug stability and safety: permeation behaviour and differences regarding their break resistance
  • Points to consider in selecting polymer vials
  • Friederike Ruebeling

    Friederike Ruebeling, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
    View Bio

    10:30 Morning Coffee

    11:00 Combination products & device delivery platforms: A winning team?

  • Device platform development for combination products: Opportunities and challenges
  • Key takeaways of a marketed inhalation device platform and how this can be applied to injectable devices
  • Fast to clinic: A (DHF) Platform Approach for PFS in clinical trials and beyond
  • Outlook Key considerations for developing successful injectable delivery platforms
  • Sabine Kattenbeck

    Sabine Kattenbeck, Head Device Project Management, Boehringer Ingelheim Pharma GmbH & Co. KG
    View Bio

    Gabriele Widerstein

    Gabriele Widerstein, Device Lead, Boehringer Ingelheim GmbH
    View Bio

    11:40 Key design considerations for an emergency-use injection system

    John Burke

    John Burke, Senior Industrial Design Consultant, Team Consulting Limited
    View Bio

  • How to optimize user experience: the design and usability challenges of an emergency-use device
  • Achieving five nines reliability
  • Sustainability choices in your development
     
  • 12:20 Networking Lunch

    13:20 Taking a sustainable approach for parenteral delivery device development

  • An overview of GSK’s roadmap to reduce environmental impact
  • Insights into sustainable approaches to class I medical devices and packaging 
  • Initial approaches to optimising device development practices for a reduced environmental footprint
  • Challenges in sustainable device development and looking forward
  • Steve Chamberlain

    Steve Chamberlain, Director Device Engineering, GSK
    View Bio

    Conor O'Neill

    Conor O'Neill, Director Head, Packaging Development & Design, GSK

    14:00 Case Study: An insight into Chiesi’s UK take-back pilot

    Harriet Lewis

    Harriet Lewis, Head of Public Affairs, Chiesi Ltd
    View Bio

  • Understanding current challenges in inhaler disposal and sustainability
  • An exploration into Chiesi’s pilot scheme for efficient inhaler recycling
  • Key takeaways from the pilot and assessing user feedback
  • Looking to the future, how can the learnings from this pilot be applied to enhancing sustainability throughout the drug delivery device industry
  •  

    14:40 Afternoon Tea

    15:10 The power of collaboration to deliver sustainable healthcare

    Fiona Adshead

    Fiona Adshead, Chair, Sustainable Healthcare Coalition
    View Bio

  • The presentation will outline how the Sustainable Healthcare Coalition, a partnership of leading companies and public sector agencies, addresses some of the most pressing sustainability issues in global healthcare.
  • Case studies of digital approaches and connected devices will demonstrate how healthcare sector industry partners can help the NHS achieve NetZero and bring together clinicians and industry to meet the challenges of improving sustainability through innovation.
     
  • 15:50 Presentation to be confirmed

    John Kearns

    John Kearns, R&D Project Manager, Teva Ltd

  • Points to be confirmed
  • 16:30 Chairman’s Closing Remarks and Close of Day Two

    Joel Richard

    Joel Richard, Chief Development Officer, MedinCell
    View Bio

    +

    FEATURED SPEAKERS

    Clemens Gunther

    Clemens Gunther

    Director, Senior Expert Nonclinical Safety, Bayer AG
    Cristiana Heese

    Cristiana Heese

    Packaging Engineer Combination Products, Boehringer Ingelheim Pharma Gmbh & Co. Kg
    David Deutsch

    David Deutsch

    Leading Senior Pharmaceutical Assessor, MHRA
    Fatima Bennai-Sanfourche

    Fatima Bennai-Sanfourche

    Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG
    Fiona Adshead

    Fiona Adshead

    Chair, Sustainable Healthcare Coalition
    Friederike Ruebeling

    Friederike Ruebeling

    Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
    Gabriele Widerstein

    Gabriele Widerstein

    Device Lead, Boehringer Ingelheim GmbH
    Harriet Lewis

    Harriet Lewis

    Head of Public Affairs, Chiesi Ltd
    Joel Richard

    Joel Richard

    Chief Development Officer, MedinCell
    John Burke

    John Burke

    Senior Industrial Design Consultant, Team Consulting Limited
    Julia Frese

    Julia Frese

    Director, TUV SUD Japan Ltd.
    Michael Becker

    Michael Becker

    Packaging Engineer, Launch & Transfer Operations, Boehringer Ingelheim Pharma GmbH & Co. KG
    Prashant Bhatia

    Prashant Bhatia

    Associate Director, AstraZeneca
    Rene Holm

    Rene Holm

    Professor, University of Southern Denmark
    Sabine Kattenbeck

    Sabine Kattenbeck

    Head Device Project Management, Boehringer Ingelheim Pharma GmbH & Co. KG
    Steve Chamberlain

    Steve Chamberlain

    Director Device Engineering, GSK

    Clemens Gunther

    Director, Senior Expert Nonclinical Safety, Bayer AG
    Clemens Gunther

    Dr. Clemens Günther received his diploma in biology and doctorate for natural sciences from the Free University, Berlin-Germany. He started his professional career in 1990 at Schering AG, Berlin-Germany. From 2007 to 2013, Dr. Clemens Günther was Director and Head of Global Preclinical Development at Intendis GmbH, branded later-on as Bayer Dermatology. After integration of Intendis into Bayer in 2013, he became Director Nonclinical Safety Consumer Care and later-on Senior Expert Nonclinical Safety within the Division of Bayer Pharmaceuticals. Meanwhile Dr. Clemens Günther has gained over 30 years experience in drug development. He has been involved in nonclinical development and regulatory toxicology of small molecules, biologics, medical devices and drug device combination products in various medical indications.
     

    Conor O'Neill

    Director Head, Packaging Development & Design, GSK
    Conor O'Neill

    Cristiana Heese

    Packaging Engineer Combination Products, Boehringer Ingelheim Pharma Gmbh & Co. Kg
    Cristiana Heese

    David Deutsch

    Leading Senior Pharmaceutical Assessor, MHRA
    David Deutsch

    Fatima Bennai-Sanfourche

    Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG
    Fatima Bennai-Sanfourche

    Fiona Adshead

    Chair, Sustainable Healthcare Coalition
    Fiona Adshead

    Fiona chairs the Sustainable Healthcare Coalition that inspires partnerships and action on sustainable healthcare. She also works as an independent expert advisor and board member for national and global organisations on wellbeing and sustainability.

    She is a high-profile wellbeing and public health leader with a track record of reframing thinking and developing innovative strategy and programmes at the heart of business and government. Her previous roles include Deputy Chief Medical Officer and Director General in the UK Government, Director of Chronic Disease and Health Promotion at the World Health Organisation and Bupa’s Chief Wellbeing Officer.

    Fiona is a visiting Professor at UCL and teaches at Cambridge Institute for Sustainability Leadership. Fiona’s recent board roles include British Land’s Sustainability Advisory Panel, Marks and Spencer’s Sustainable Retail Advisory Board, and Business in the Community’s Wellbeing Leadership Team.


     

    Friederike Ruebeling

    Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
    Friederike Ruebeling

    Dr. Friederike Ruebeling studied chemical and process engineering at the university in Karlsruhe (Karlsruhe Institute of Technology, KIT), where she also wrote her PhD thesis about the microstructure evolution in copper due to tribological loading. After her PhD, she started working at Boehringer Ingelheim Pharma GmbH & Co. KG as a Postdoc. Now in a scientist position within the Primary Packaging and Process Development group, she investigates the suitability of various primary packaging materials with a particular focus on vials and pre-fillable syringes.

    Gabriele Widerstein

    Device Lead, Boehringer Ingelheim GmbH
    Gabriele Widerstein

    Gabriele Widerstein is a chemical engineer by education and 20+ years of industrial experience with a strong focus on Project Management as well as Quality & Regulatory Compliance in various fields of pharma industry (esp. in development & lifecycle management of medical devices and combination products).
    Since 2019 she leads project teams for the development of devices/combination products.
    Prior to this role she provided project specific and overarching quality and regulatory input and guidance at Sanofi to develop devices and combination products for submission and throughout end of lifecycle.
     

    Harriet Lewis

    Head of Public Affairs, Chiesi Ltd
    Harriet Lewis

    Harriet studied Pharmacy at University of Manchester followed by a postgraduate diploma in Public Health at University of Salford and practised as a pharmacist in both primary and secondary care.
    Harriet joined Chiesi in January 2018 to lead a new team for the UK business focusing on medicines policies, sustainability and NHS engagement.

    Harriet spent much of her early career in the NHS in a number of medicines and policy roles including Associate Director for Medicines Advice at the National Institute for Care Excellence (NICE), Head of Medicines Policy for the National Prescribing Centre (NPC) and Head of Pharmacy Services for Trafford Primary Care Trust (PCT).

    Harriet is currently leading the Chiesi UK External Sustainability Programme, focusing on Chiesi’s B Corp status, reducing the environmental impact of inhalers, the introduction of next generation lower carbon solutions and a new inhaler postal recycling scheme. Harriet has a strong commitment for demonstrating leadership and supporting other businesses to start on their sustainability journeys – to this end she leads the Industry trade association (ABPI) Sustain group, co-leads the UK subteam of the International Pharmaceutical Aerosol Consortium (IPAC) and is one of the UK champions for the B Lab Boardroom 2030 initiative.

     

     

     

     

    Joel Richard

    Chief Development Officer, MedinCell
    Joel Richard

    Dr Joël Richard is currently Executive Committee Member and Head of Technical & Pharmaceutical Operations at MedinCell (Montpellier, France). He is leading all the development activities of the company, based on the proprietary technology BEPO® for Long-Acting Injectables. (LAIs). These activities comprise formulation and process development, device development, analytical development, process transfer and scale-up, manufacturing and supply of clinical batches, regulatory affairs and clinical development operations, quality and regulatory compliance. Dr Richard has more than 30 years of experience in chemistry and (bio)pharmaceutical R&D, including several global senior leadership positions in various Biotech and Pharma companies, such as Ipsen (France), Serono (Italy), MerckSerono (Germany), Ethypharm (France). Dr Richard has focused his research activity on new formulation technologies and innovative drug delivery systems (microspheres, nanosystems, self-assembling gels), especially for injectable peptide and protein formulations. He has graduated from Ecole Normale Supérieure (Cachan, France), and got a PhD in Materials Science (Paris VI, France), and the “Habilitation à Diriger les Recherches” in Chemistry (Bordeaux I, France). He has published 69 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields. He is the author of 140 international communications and 55 patent families. He has also been serving as an APGI Board Member for 3 years and is a Member of the Controlled Release Society (CRS).

     

    John Burke

    Senior Industrial Design Consultant, Team Consulting Limited
    John Burke

    John specialises in the design and project management of medical devices, with a particular focus on the development of parenteral drug delivery devices. A designer by training with a strong grounding in medical design and regulatory focused human factors, he regularly attends user studies in both Europe and the US.
    John brings experience of both consumer and medical product development, having worked on a diverse range of products, including drug delivery devices, wound management, diagnostics platforms and blood glucose monitoring. He has a degree in Product Design from Nottingham Trent University and has worked in design consultancy roles in London and Cambridge.
     

    Julia Frese

    Director, TUV SUD Japan Ltd.
    Julia Frese

    By education biomedical engineer with a Master degree in business administration. Julia gained experience in development, regulatory approval of combination devices and ATMP products. She was further involved in the development of standards for ATMP products. Currently Julia Frese is heading the division of Medical and Health Services at TÜV SÜD Japan and is responsible for the development of article 117 service within the organisation. She is further co-chair of the Team NB working group for article 117.

    Kimberley Alexander

    Principal Associate, Core Human Factors
    Kimberley Alexander

    Michael Becker

    Packaging Engineer, Launch & Transfer Operations, Boehringer Ingelheim Pharma GmbH & Co. KG
    Michael Becker

    Dr. Michael Becker (born in 1983) is working at Boehringer Ingelheim Pharma GmbH & Co. KG since 2016 as a Design Engineer for parenteral combination products and for two years for packaging and labelling. Previously, he worked for 5 years at Sanofi-Aventis GmbH in the development of Autoinjectors, Pre-filled Syringes and Injection Pens. He studied Physics at the University of Mainz and wrote his PhD thesis about the Dry Powder Inhalers supervised by Mr. Prof. Cameron Tropea (Technical University Darmstadt).

    Prashant Bhatia

    Associate Director, AstraZeneca
    Prashant Bhatia

    Rene Holm

    Professor, University of Southern Denmark
    Rene Holm

    René Holm received his pharmaceutical training at the Royal Danish School of Pharmacy, now the school of pharmacy at University of Copenhagen, Denmark, in 1998 and his PhD in biopharmaceutics from the same institution in 2002. Dr. Holm joined Lundbeck in 2001 and changed to Janssen in 2016. Dr. Holm has worked within pharmaceutical development, formulations for non-clinical testing in drug discovery, physical chemistry and material science covering both small and large molecules and is now responsible for the functional unit ensuring development of all non-solid formulations for Janssens small molecule value stream.

    Dr. Holm is (co-) author of more than 185 original articles in peer-reviewed journals and patents in the field of biopharmaceutics, preformulation, formulation and physical pharmacy and is a honorary professor in physical chemistry at the Department of Science and Environment, University of Roskilde, Denmark.


     

    Sabine Kattenbeck

    Head Device Project Management, Boehringer Ingelheim Pharma GmbH & Co. KG
    Sabine Kattenbeck

    Sabine Kattenbeck is heading the device project management group at Boehringer Ingelheim, with many years’ experience in drug regulatory affairs and medical devices. She gained major expertise in medical device development and global market introduction of a device/ combination product platform, leading crossfunctional teams from Start of Development to Launch.

    Steve Chamberlain

    Director Device Engineering, GSK
    Steve Chamberlain

    I lead the Late Stage Parenteral Engineering team within GSK’s Device Engineering department where I am responsible for the technical understanding, performance and robustness aspects of the parenteral devices within the late stage portfolio. I have a Masters degree in Mechanical & Manufacturing Engineering and, over a 13 year career at GSK, have held various positions, most notably as the Device Lead on GSK’s flagship dry powder inhalation device known as Ellipta.

     

    Exhibitors

    VENUE

    Venue To Be Confirmed

    London, United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Workshop B Agenda

    Download

    Workshop A Agenda

    Download

    Conference Co-Chair Letter

    Download

    Injectable Drug Delivery Brochure 2022

    Download

    Survey Results

    Download

    Speaker Biographies

    Download

    Past Attendees

    Download

    Past Presentation: Mark Palmer, GSK

    Download

    Past Presentation: Jonathan Sutch, BSI

    Download

    Past Presentation: Christian Dechant, Boehringer Ingelheim

    Download

    Past Presentation: Blake Green, Amgen

    Download

    Past Presentation: Amanda Matthews, Pfizer

    Download

    Exhibitors


    Owen Mumford

    Exhibitors
    http://www.owenmumford.com

    Owen Mumford Pharmaceutical Services is a specialist in the design, development and manufacture of injectable drug delivery systems for the pharmaceutical, biotech & generics industries. These include single dose and multidose reusable and disposable auto-injectors, pens and syringes for subcutaneous and intramuscular administration. Our innovative products are designed to meet both the need of our pharmaceutical partners and their patients by facilitating ease of use and improving safety and patient compliance. Our devices are also designed with aim of reducing complexity and risk for the pharmaceutical & biotech industry in the development of their combination products.

    For more information please visit https://www.ompharmaservices.com/


    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Venue To Be Confirmed

    London
    United Kingdom

    Venue To Be Confirmed

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out